HK1202027A1 - 治療或預防注意缺陷多動障礙的方法和組合物 - Google Patents

治療或預防注意缺陷多動障礙的方法和組合物

Info

Publication number
HK1202027A1
HK1202027A1 HK15102618.1A HK15102618A HK1202027A1 HK 1202027 A1 HK1202027 A1 HK 1202027A1 HK 15102618 A HK15102618 A HK 15102618A HK 1202027 A1 HK1202027 A1 HK 1202027A1
Authority
HK
Hong Kong
Prior art keywords
compositions
treating
methods
attention deficit
hyperactivity disorder
Prior art date
Application number
HK15102618.1A
Other languages
English (en)
Inventor
Michael H Davidson
Gerald L Wisler
Original Assignee
Omthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omthera Pharmaceuticals Inc filed Critical Omthera Pharmaceuticals Inc
Publication of HK1202027A1 publication Critical patent/HK1202027A1/zh

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/305Attention deficit disorder; Hyperactivity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
HK15102618.1A 2011-10-21 2015-03-16 治療或預防注意缺陷多動障礙的方法和組合物 HK1202027A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549917P 2011-10-21 2011-10-21
PCT/US2012/061131 WO2013059669A1 (en) 2011-10-21 2012-10-19 Methods and compositions for treating or preventing attention deficit hyperactivity disorder

Publications (1)

Publication Number Publication Date
HK1202027A1 true HK1202027A1 (zh) 2015-09-18

Family

ID=48141415

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15102618.1A HK1202027A1 (zh) 2011-10-21 2015-03-16 治療或預防注意缺陷多動障礙的方法和組合物
HK15102689.5A HK1202029A1 (zh) 2011-10-21 2015-03-17 治療或預防注意缺陷多動障礙的方法和組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15102689.5A HK1202029A1 (zh) 2011-10-21 2015-03-17 治療或預防注意缺陷多動障礙的方法和組合物

Country Status (6)

Country Link
US (2) US20140316003A1 (zh)
EP (1) EP2806736A4 (zh)
JP (1) JP2015501426A (zh)
CN (1) CN104168766A (zh)
HK (2) HK1202027A1 (zh)
WO (1) WO2013059669A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103902A1 (en) 2012-01-06 2013-07-11 Omthera Pharmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2846779A4 (en) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
US20150141513A1 (en) * 2012-05-10 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders and neurological diseases
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US20220082576A1 (en) * 2019-01-03 2022-03-17 Pontificia Universidad Catolica De Chile Biochemical diagnostic test for attention-deficit/hyperactivity disorder (adhd)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855949A (en) * 1994-01-10 1999-01-05 Mclean; Linsey Dietary system high in oil intake
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−3脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
EP1888081B1 (en) * 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
CN101506218A (zh) * 2005-05-23 2009-08-12 麻省理工学院 含有多不饱和脂肪酸的组合物及其使用方法
EP1968567B1 (en) * 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
WO2008147562A2 (en) * 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
WO2011115476A1 (en) * 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
US20110287975A1 (en) * 2010-05-14 2011-11-24 The Johns Hopkins University Methods and Compositions for Correlating Genetic Markers with Conversion of Medium Chain Polyunsaturated Fatty Acids to Long Chain Polyunsaturated Fatty Acids

Also Published As

Publication number Publication date
US20160124003A1 (en) 2016-05-05
CN104168766A (zh) 2014-11-26
HK1202029A1 (zh) 2015-09-18
EP2806736A1 (en) 2014-12-03
US20140316003A1 (en) 2014-10-23
JP2015501426A (ja) 2015-01-15
WO2013059669A1 (en) 2013-04-25
EP2806736A4 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
ZA201307649B (en) Methods and compositions for treatment of attention deficit disorder
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
HK1209798A1 (zh) 用於治療癌症的組合物和方法
IL227429A0 (en) The components and methods of cancer treatment
EP2755482A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
HK1201475A1 (zh) 治療疼痛的方法和組合物
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2890720A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
HUE050192T2 (hu) Készítmény és eljárás vízrendszerek kezelésére
EP2771341A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
ZA201404187B (en) Compositions and methods for treating dental conditions
EP3054935A4 (en) Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
GB2496343B (en) A method of treating attention deficit hyperactivity disorder
IL232648A0 (en) Preparations and methods for treating glioma
HK1202029A1 (zh) 治療或預防注意缺陷多動障礙的方法和組合物
IL229231A0 (en) Preparations and methods for the treatment of cancer
HK1216854A1 (zh) 用於治療癌症的組合物和方法
HK1188566A1 (zh) 治療癌症的組合物和方法
EP2846789A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTISM AND AUTISM SPECTRUM DISORDER
HK1202260A1 (zh) 宿醉的預防劑及/或治療劑
EP2812487A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF MEDIA
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2822593A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2714082A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
GB201122124D0 (en) Compositions and methods for treating biofilms